| It's almost there, Rzr. We are advancing new technologies daily!
"JDRF-funded researchers in Boston have developed a drug therapy that shows promise in blocking rejection of transplanted tissue without undermining the immune system’s long-term effectiveness. The therapy, devised by scientists at Beth Israel Deaconess Medical Center at Harvard Medical School, raises the possibility that anti-rejection drugs could be used for a short period after an islet transplant and then discontinued, freeing the patient from lifelong immune suppression. " | 
